Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer (PRIMUS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Biothera
Sponsor:
Information provided by (Responsible Party):
Biothera
ClinicalTrials.gov Identifier:
NCT01309126
First received: February 8, 2011
Last updated: August 15, 2014
Last verified: August 2014

February 8, 2011
August 15, 2014
April 2011
April 2016   (final data collection date for primary outcome measure)
Overall Survival (OS) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01309126 on ClinicalTrials.gov Archive Site
  • Progression Free Survival (PFS) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Rate of complete response (CR) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Rate of partial response (PR) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Rate of overall response (CR + PR) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Safety and tolerability of the dosing regimen as measured by the incidence and severity of adverse events observed in study participants [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Sparse pharmacokinetic profile of Imprime PGG will be determined to expand current Imprime PGG PK data [ Time Frame: 18 months ] [ Designated as safety issue: No ]
    Samples for sparse PK will be taken at specified times on Cycle 1/Day 1 in the first 30 available subjects randomized to Arm 1 (Subjects 1-30). Samples will be collected, at multiple times, in the next 60 subjects randomized to Arm 1 who reach Cycle 2/Day 1 of dosing (subjects 31-90). Additionally, any subject after the first 90 subjects (subjects 91-795) who have a screening/baseline calculated creatinine clearance (based on age, weight and serum creatinine) of <60 mL/minute will have sparse PK samples collected.
  • Change in Quality of Life [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Progression Free Survival (PFS) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Rate of complete response (CR) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Rate of partial response (PR) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Rate of overall response (CR + PR) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Safety and tolerability of the dosing regimen as measured by the incidence and severity of adverse events observed in study participants [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Sparse pharmacokinetic profile of Imprime PGG will be determined to expand current Imprime PGG PK data [ Time Frame: 18 months ] [ Designated as safety issue: No ]
    Sparse sampling will be conducted in first 90 enrolled in Arm 1 and any subject in Arm 1 with a creatinine clearance <60mL/min (analyses to include area under the curve, maximum concentration, and half-life determinations).
  • Change in Quality of Life [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Study BT-CL-PGG-CRC1031 is a Phase 3, open-label, randomized, multi-center study. Qualified subjects, who have KRAS wild type (WT) colorectal cancer will be randomized in a 2:1 ratio to treatment with either Imprime PGG and cetuximab or cetuximab alone. Subjects will be dosed until progression or discontinuation for some other reason. Efficacy will be assessed via Response Evaluation Criteria in Early Tumors 1.1 (RECIST 1.1); computed tomography (CT) scans will be conducted every 6 weeks. Safety, pharmacokinetics (PK), quality of life, and biomarker parameters will also be assessed.

Study BT-CL-PGG-CRC1031 is a Phase 3, open-label, randomized, multi-center study. Qualified subjects, who have KRAS WT colorectal cancer will be randomized in a 2:1 ratio to either:

Arm 1: Imprime PGG and cetuximab or Arm 2: Cetuximab

Approximately 795 subjects will be randomized into the study. Dosing will occur in 6-week cycles. Imprime PGG will be dosed at 4 mg/kg and will be administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36) preceding the administration of cetuximab (Arm 1 only). The initial cetuximab dose (both arms) will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2 administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36).

Subjects will be dosed until progressive disease (PD) per RECIST 1.1 or discontinuation of study drug for other reasons; e.g., safety. Following completion of the treatment period of the study, subjects will be monitored for survival until death or loss to follow-up. Tumor measurements and determination of tumor responses will be evaluated according to RECIST 1.1. Safety, PK, quality of life, and biomarker parameters will also be assessed.

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Colorectal Cancer
  • Biological: Imprime PGG + cetuximab
    Imprime PGG: 4 mg/kg and will be administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36) preceding the administration of cetuximab Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
    Other Names:
    • Imprime PGG
    • Cetuximab (Erbitux)
  • Drug: Cetuximab
    Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
    Other Name: Cetuximab (Erbitux)
  • Experimental: Arm 1: Imprime PGG + cetuximab
    Biological/Vaccine + Drug
    Intervention: Biological: Imprime PGG + cetuximab
  • Active Comparator: Arm 2: cetuximab
    Drug
    Intervention: Drug: Cetuximab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
795
December 2016
April 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Is >18 years old;
  2. Has recurrent or metastatic carcinoma of the colon or rectum with documented histological or cytological confirmation;
  3. Must be KRAS WT;
  4. Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion according to RECIST 1.1;
  5. Has never received cetuximab or panitumumab, and has not received any treatment for colorectal cancer within 30 days prior to the first dose of study treatment under this protocol;
  6. Has an Eastern Cooperative Oncology Group (ECOG) score of 0-1, with a life expectancy of >3 months;
  7. Has received at least 2 prior chemotherapeutic regimens for colorectal cancer;
  8. Has adequate bone marrow reserve as evidenced by:

    • Absolute neutrophil count ≥1,500/μL
    • Platelets ≥100,000/μL;
  9. Has adequate renal function as evidenced by serum creatinine ≤2.5 × the upper limit of normal (ULN) for the reference lab;
  10. Has adequate hepatic function as evidenced by:

    • Aspartate aminotransferase ≤3 × ULN for the reference lab (≤5 × ULN for subjects with known hepatic metastases)
    • Alanine aminotransferase ≤3 × ULN for the reference lab (≤5 × ULN for subjects with known hepatic metastases)
    • Bilirubin <1.5 mg/dL or direct bilirubin <1.0 mg/dL
    • Serum Albumin >3.0 gm/dL
  11. Has read, understood and signed the informed consent form (ICF) approved by the Independent Review Board/Independent Ethics Committee (IRB/IEC); and
  12. If the subject is a woman of childbearing potential or a fertile man, he/she must agree to use an effective form of contraception during the study and for 60 days following the last dose of study drug (an effective form of contraception is abstinence, a hormonal contraceptive, or a double-barrier method).

Exclusion Criteria:

  1. Has a known hypersensitivity to cetuximab, murine proteins, or any component of cetuximab;
  2. Has a known hypersensitivity to baker's yeast or has an active yeast infection;
  3. Has had previous exposure to Betafectin® or Imprime PGG;
  4. Has an active, uncontrolled infection;
  5. Has known untreated or symptomatic brain metastases;
  6. Had a second malignancy within the previous 5 years, except for basal cell carcinoma, cervical intra-epithelial neoplasia or treated prostate cancer with a prostate-specific antigen (PSA) of <2.0 ng/mL;
  7. Has known human immunodeficiency virus or acquired immune deficiency syndrome, hepatitis B, hepatitis C, connective tissue disease, or other clinical diagnosis, ongoing or intercurrent illness that in the Investigators opinion should preclude the subject from participation;
  8. If female, is pregnant or breast-feeding;
  9. Is receiving concurrent standard and/or investigational anti-cancer therapy or has received such therapy within a period of 30 days prior to the first scheduled day of dosing (investigational therapy is defined as treatment for which there is currently no regulatory-authority-approved indication); or
  10. Has previously received an organ or progenitor/stem cell transplant.
Both
18 Years and older
No
Contact: Nick Niles 908-453-3317 nniles@cmedresearch.com
United States,   France,   Germany,   Puerto Rico
 
NCT01309126
BT-CL-PGG-CRC1031
Yes
Biothera
Biothera
Not Provided
Not Provided
Biothera
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP